The collection of discussions demonstrates a strong overall support for daprodustat’s efficacy and safety, with many posts referencing specific trial results and safety outcomes using technical language, which indicates high engagement and interest. Words like 'noninferior,' 'comparable,' and phrases such as 'approval of this HIF-PHI' reflect a tone of cautious optimism and professional relevance, indicating their potential impact on treatment options.
AgreementModerate agreement
Most discussions support the idea that daprodustat is effective and safe, emphasizing its noninferiority to traditional treatments.
InterestHigh interest
The majority show high engagement and curiosity about the study results, safety profile, and approval status.
EngagementHigh engagement
Posts reference detailed trial outcomes, safety data, and comparisons with existing therapies, indicating deep interest.
ImpactModerate impact
The discussions highlight daprodustat's potential to influence current treatment practices, though some focus remains on ongoing approval and safety, not full clinical adoption.
Abstract in brief
A phase 3 trial compared the effectiveness of an oral drug called daprodustat to injectable erythropoiesis-stimulating agents (ESAs) in increasing hemoglobin levels in CKD patients on dialysis with low hemoglobin.
Results showed that daprodustat increased hemoglobin by an average of 0.28 g/dL, while the ESA group had an increase of 0.10 g/dL, indicating that daprodustat was noninferior to ESAs.
Cardiovascular events were similar in both groups, with 25.2% of daprodustat patients and 26.7% of ESA patients experiencing major adverse events, confirming dap
In this phase 3 clinical trial, daprodustat was effective as a treatment for anemia in patients with CKD who were undergoing maintenance hemodialysis or peritoneal dialysis. #KidneyWk https://t.co/ykzSsUlJci https://t.co/0zdlMyOlTf
Nov 5, 2021 · 16 likes · 9 shares · 935,281 followersView post →
DC
Daniel Coyne
@DrDanMO · X
Dapro is comparable on efficacy and safety to ESA in Dialysis Dependent patient...
#ASN
https://t.co/yPCY5xs4Qw https://t.co/kXthJ16tJE
Nov 5, 2021 · 6 likes · 3,534 followersView post →
PR
Pharmacy Residency
@Phresidency · X
We enjoyed today half day educational activity titled “Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis (ASCEND-D trial)” presented by Dr. Aliyah Alorayyidh, R2 Pharmacy Resident https://t.co/RLH6qWNRXw
Feb 21, 2023 · 4 likes · 1,649 followersView post →
SS
Swapnil Hiremath @hswapnil.medsky.social
@hswapnil · X
ASCEND dialysis link https://t.co/v40Dp3sxjP https://t.co/PeUYV4MPpL
Oct 27, 2022 · 3 likes · 21,712 followersView post →
In 2023, the FDA approved daprodustat as the first oral treatment for anemia in dialysis patients with CKD. This video explains how daprodustat increases hemoglobin levels, demonstrating efficacy and safety comparable…
In this academic review, Professor Matthias Girndt presents key studies from 2021, focusing on significant findings from the DAPA-CKD trial. The trial demonstrated that dapagliflozin effectively reduces kidney…
【文献メモ】〈ASCEND-D Study〉
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
(N. Engl. J. Med. 2021, 385, 2325-2335.)
https://t.co/431m1wAnFQ
14) #Daprodustat: On the left here, you see the HIF-PHI vs #ESA in #dialysis pts ➡️ noninferior. On the R, see #MACE, #MACE+, & ☠️: no difference.
These data ➡️ approval of so far the only #HIF_PHI to be approved in
Nov 29, 2023 · 1 like · 2,647 followersView post →
HD
Hematology & Thromboembolic Diseases
@Hematology123 · X
Daprodustat for the Treatment of #Anemia in Patients Undergoing #Dialysis
For More: https://t.co/vqDE02Tc4c
17) #Daprodustat was next in the #FDA docket. Its trial in #CKD-#Dialysis patients vs #ESA showed comparable #MACE safety (HR 0.93 (95% CI 0.81-1.07). An endpoint of MACE events or #thrombotic events was also similar between therapies.
See
Jun 14, 2023 · 2 likes · 2,647 followersView post →
CC
@CKD_ce
@ckd_ce · X
11a) And here is a trial in #dialysis patients already on #ESA and at Hb goal, randomized to #Daprodustat or an ESA. Again, both therapies maintained Hb in the desired range for up to 148 weeks.
See
Jun 14, 2023 · 1 like · 2,647 followersView post →
PR
Pharmacy Residency
@Phresidency · X
We enjoyed today half day educational activity titled “Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis (ASCEND-D trial)” presented by Dr. Aliyah Alorayyidh, R2 Pharmacy Resident https://t.co/RLH6qWNRXw
Feb 21, 2023 · 4 likes · 1,649 followersView post →
GM
Graham Abra, MD
@GrahamAbra · X
@SBansalNeph @DoctorAjaySingh ~11% of the cohort in study below were on PD
https://t.co/cuyUh8eDBH
Feb 3, 2023 · 3 likes · 2,670 followersView post →
DG
Dr.Barry UreaAide,Nephrologist,Prof,PI,GirlDad
@KidneyAide · X
Daprodustat approved for Dialysis #Anemia based on ASCEND-D trial
#HIFPHI (“Hi Fi”)
#nephrology #NephTwitter #Nephpearls #MedEd #hematology
https://t.co/AWkBCJloso
https://t.co/89xE4QyFle
35) #Daprodustat
#ASCEND studies in #CKD/#ESKD
Noninferior to ESAs for hgb goals and #CV outcomes in ESKD
Similar in CKD vs #ESA for target Hgb and CV outcomes
See
El tratamiento de la anemia en pacientes sometidos a diálisis.
Te invitamos a conocer más sobre este importante tema de salud: https://t.co/3NiLr0e6f3
#Salud #research
@GuyattGH Will the change of non-inferiority margin after the trial has begun affect the conclusions of the trial? See this trial https://t.co/9Stk0rOAq4 https://t.co/ELLw0gbpBF
Feb 17, 2022 · 1 like · 2,251 followersView post →
UT
Uber Turco
@CAdabag · X
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis https://t.co/Nf9B9ambyh
RT @TransfusionLib: New from #Transfusion Evidence Library:
#Daprodustat for the Treatment of #Anemia in Patients Undergoing #Dialysis by…
Dec 17, 2021 · 2 shares · 666 followersView post →
B
BigNige
@BigNige73593282 · X
RT @TransfusionLib: New from #Transfusion Evidence Library:
#Daprodustat for the Treatment of #Anemia in Patients Undergoing #Dialysis by…
Dec 16, 2021 · 2 shares · 233 followersView post →
TL
Transfusion Library
@TransfusionLib · X
New from #Transfusion Evidence Library:
#Daprodustat for the Treatment of #Anemia in Patients Undergoing #Dialysis by Singh et al.
https://t.co/12LauN3zs5 https://t.co/DktqhPgVSf
Dec 16, 2021 · 2 likes · 2 shares · 3,309 followersView post →
ML
Milton Larrondo
@miltonlarrondo · X
Que les parece a mis amig@s nefrólogos. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis | NEJM https://t.co/FeqUqvncF0
#PUblicaSalutIB Tractament de l’anèmia de la insuficiència renal amb estabilitzadors del factor induït per la hipòxia (HIF) via oral https://t.co/uTs72joP3i @SonEspases https://t.co/7uJfeoAwvs https://t.co/RoJs2fnoaK
#PUblicaSalutIB Tratamiento de la anemia de la insuficiencia renal con estabilizadores del factor inducido por la hipoxia (HIF) vía oral https://t.co/aVJaKULwPj @SonEspases https://t.co/OJgLXZKYSX https://t.co/LnFM4e53xX
Nov 24, 2021 · 1 like · 1 share · 4,409 followersView post →
I
Infosalut
@infosalut · X
#PUblicaSalutIB Tractament de l’anèmia de la insuficiència renal amb estabilitzadors del factor induït per la hipòxia (HIF) via oral https://t.co/ECr9qaYeJ6 @SonEspases https://t.co/OJgLXZKYSX https://t.co/mkTTHDQYgs
Nov 12, 2021 · 3 likes · 3,018 followersView post →
BN
Bertrand Neveux
@NeveuxBertrand · X
#Dialyse: le Daprodustat aussi sûr et efficace que le traitement conventionnel de l' #anémie chez les patients atteints d'insuffisance rénale, mais sans les effets secondaires cardiovasculaires !
https://t.co/N41CUD6ztI https://t.co/DT0ajS8lPd
RCT: In patients with chronic kidney disease and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes – via @NEJM
https://t.co/B5jEMJ0rbM
News release: https://t.co/uagA723WVY
Nov 8, 2021 · 1 like · 29,363 followersView post →
TL
the paper link
@the_paper_link · X
Trend new: Singh AK, ..., Ascend-d Study Group (N Engl J Med) __Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis__
https://t.co/EeKO7moNpb
$GSK data on its HIF-PH inhibitor daprodustat published in NEJM:
https://t.co/YI3scTYVrd
https://t.co/EGTT1zrYVG
(Non dialysis on left below, dialysis on right) https://t.co/c5AaIf5LRQ
Dapro is comparable on efficacy and safety to ESA in Dialysis Dependent patient...
#ASN
https://t.co/yPCY5xs4Qw https://t.co/kXthJ16tJE
Nov 5, 2021 · 6 likes · 3,534 followersView post →
PM
Pub Health Monitor
@monitor_PH · X
RT @NEJM: In this phase 3 clinical trial, daprodustat was effective as a treatment for anemia in patients with CKD who were undergoing main…
Nov 5, 2021 · 9 shares · 1,822 followersView post →
N
NEJM
@NEJM · X
In this phase 3 clinical trial, daprodustat was effective as a treatment for anemia in patients with CKD who were undergoing maintenance hemodialysis or peritoneal dialysis. #KidneyWk https://t.co/ykzSsUlJci https://t.co/0zdlMyOlTf
Nov 5, 2021 · 16 likes · 9 shares · 935,281 followersView post →
KM
Kenar Jhaveri, MD
@kdjhaveri.bsky.social · Bluesky
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2113380
and the dialysis trial is live on @NEJM as well https://t.co/pF6b67UUZ7
#KidneyWk
Again MACE - point estimate favorable https://t.co/jVGrcZWMIk
Nov 5, 2021 · 1 like · 21,712 followersView post →
N
approach-to-anemia.pdf
News
... 10.1056/NEJMoa2113379 ○ Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHIs) are as effective as erythropoiesis-stimulating agents (ESAs) in ...
fphar-14-1274490 | PDF | Medical Specialties | Clinical Medicine
News
N. (2020). A single-dose, open-label, randomized, two-way crossover study in healthy Japanese Engl. J. Med. 385 (25), 2325–2335. doi:10.1056/nejmoa2113379
... 10.1056/NEJMoa2113379 PubMed et al.; for Conference Participants: Novel anemia therapies in chronic kidney 75. Natale P, Palmer SC, Jaure A, Hodson EM ...
Sharon Lilibeth Vivanco Ramírez Dr. Victor Lanchi Zúñiga | PDF ...
News
... 10.1056/NEJMoa2113379 (Hiddo J.L. ... Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. https://doi.org/10.1056/NEJMoa2113379
Oral pill as safe, efficacious as conventional treatment for anemia in ...
News
... 10.1056/NEJMoa2113379. Journal. New England Journal of Medicine. DOI. 10.1056/NEJMoa2113380. Method of Research. Randomized controlled/clinical ...
N
DC
PR
SS
南P
GM
文
CC
HD
DG
に
UD
IU
MK
UT
AN
BA
令
パ牡
SI
B
TL
ML
B
ほ
I
Y
猫
T
P
BN
DC
TL
UA
HC
T北
EG
R
JR
NP
MM
PM